Predictive biomarkers are expected to witness significant growth in the clinical phase outsourcing services market due to their ability to predict patient response to specific treatments.
Prognostic biomarkers are also anticipated to drive market growth as they provide insights into the likely course of a disease, aiding in treatment decision-making.
Surrogate biomarkers, although less commonly used, are gaining traction in outsourcing services for their potential to substitute for a clinical endpoint in evaluating treatment efficacy.
Therapeutic Area:
Oncology is projected to be the largest segment in the biomarker clinical phase outsourcing services market, driven by the increasing focus on personalized medicine and targeted therapies in the field.
Neurology is expected to be another key therapeutic area, with growing demand for biomarkers to aid in the diagnosis and management of neurological disorders.
End-user:
Pharmaceutical and biotechnology companies are the primary end-users of biomarker clinical phase outsourcing services, as they seek to leverage biomarkers to streamline drug development processes and improve patient outcomes.
Outsourcing services providers play a crucial role in assisting these companies in biomarker discovery, validation, and implementation in clinical trials.